Literature DB >> 30343466

Resveratrol Preconditioning Induces Genomic and Metabolic Adaptations within the Long-Term Window of Cerebral Ischemic Tolerance Leading to Bioenergetic Efficiency.

Nathalie Khoury1,2,3, Jing Xu1,2,3, Samuel D Stegelmann1,2, Charles W Jackson1,2,3, Kevin B Koronowski1,2,3, Kunjan R Dave1,2,3, Juan I Young3,4,5, Miguel A Perez-Pinzon6,7,8.   

Abstract

Neuroprotective agents administered post-cerebral ischemia have failed so far in the clinic to promote significant recovery. Thus, numerous efforts were redirected toward prophylactic approaches such as preconditioning as an alternative therapeutic strategy. Our laboratory has revealed a novel long-term window of cerebral ischemic tolerance mediated by resveratrol preconditioning (RPC) that lasts for 2 weeks in mice. To identify its mediators, we conducted an RNA-seq experiment on the cortex of mice 2 weeks post-RPC, which revealed 136 differentially expressed genes. The majority of genes (116/136) were downregulated upon RPC and clustered into biological processes involved in transcription, synaptic signaling, and neurotransmission. The downregulation in these processes was reminiscent of metabolic depression, an adaptation used by hibernating animals to survive severe ischemic states by downregulating energy-consuming pathways. Thus, to assess metabolism, we used a neuronal-astrocytic co-culture model and measured the cellular respiration rate at the long-term window post-RPC. Remarkably, we observed an increase in glycolysis and mitochondrial respiration efficiency upon RPC. We also observed an increase in the expression of genes involved in pyruvate uptake, TCA cycle, and oxidative phosphorylation, all of which indicated an increased reliance on energy-producing pathways. We then revealed that these nuclear and mitochondrial adaptations, which reduce the reliance on energy-consuming pathways and increase the reliance on energy-producing pathways, are epigenetically coupled through acetyl-CoA metabolism and ultimately increase baseline ATP levels. This increase in ATP would then allow the brain, a highly metabolic organ, to endure prolonged durations of energy deprivation encountered during cerebral ischemia.

Entities:  

Keywords:  Acetyl-CoA; Brain metabolism; Brain transcriptomic; Cerebral ischemia; Preconditioning; Resveratrol

Mesh:

Substances:

Year:  2018        PMID: 30343466      PMCID: PMC6475499          DOI: 10.1007/s12035-018-1380-6

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  13 in total

1.  Ischemic Neuroprotectant PKCε Restores Mitochondrial Glutamate Oxaloacetate Transaminase in the Neuronal NADH Shuttle after Ischemic Injury.

Authors:  Jing Xu; Nathalie Khoury; Charles W Jackson; Iris Escobar; Samuel D Stegelmann; Kunjan R Dave; Miguel A Perez-Pinzon
Journal:  Transl Stroke Res       Date:  2019-08-31       Impact factor: 6.829

2.  Mitochondria as the memory of preconditioning.

Authors:  Sarah Zerimech; Hung Nguyen; Selva Baltan
Journal:  Cond Med       Date:  2021-08-21

Review 3.  Metabolic and Cellular Compartments of Acetyl-CoA in the Healthy and Diseased Brain.

Authors:  Agnieszka Jankowska-Kulawy; Joanna Klimaszewska-Łata; Sylwia Gul-Hinc; Anna Ronowska; Andrzej Szutowicz
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

Review 4.  Polyphenols for the Treatment of Ischemic Stroke: New Applications and Insights.

Authors:  Shuhan Liu; Feng Lin; Jian Wang; Xiaoqiang Pan; Liguang Sun; Wei Wu
Journal:  Molecules       Date:  2022-06-29       Impact factor: 4.927

5.  Refocusing the Brain: New Approaches in Neuroprotection Against Ischemic Injury.

Authors:  Cristina Rodriguez; Jesús Agulla; María Delgado-Esteban
Journal:  Neurochem Res       Date:  2020-03-18       Impact factor: 3.996

Review 6.  The new role of F1Fo ATP synthase in mitochondria-mediated neurodegeneration and neuroprotection.

Authors:  Nelli Mnatsakanyan; Elizabeth Ann Jonas
Journal:  Exp Neurol       Date:  2020-07-10       Impact factor: 5.330

Review 7.  Neuroprotective Phytochemicals in Experimental Ischemic Stroke: Mechanisms and Potential Clinical Applications.

Authors:  Hui Xu; Emily Wang; Feng Chen; Jianbo Xiao; Mingfu Wang
Journal:  Oxid Med Cell Longev       Date:  2021-04-28       Impact factor: 6.543

8.  New Mechanistic Insights, Novel Treatment Paradigms, and Clinical Progress in Cerebrovascular Diseases.

Authors:  Johannes Boltze; Jaroslaw A Aronowski; Jerome Badaut; Marion S Buckwalter; Mateo Caleo; Michael Chopp; Kunjan R Dave; Nadine Didwischus; Rick M Dijkhuizen; Thorsten R Doeppner; Jens P Dreier; Karim Fouad; Mathias Gelderblom; Karen Gertz; Dominika Golubczyk; Barbara A Gregson; Edith Hamel; Daniel F Hanley; Wolfgang Härtig; Friedhelm C Hummel; Maulana Ikhsan; Miroslaw Janowski; Jukka Jolkkonen; Saravanan S Karuppagounder; Richard F Keep; Inga K Koerte; Zaal Kokaia; Peiying Li; Fudong Liu; Ignacio Lizasoain; Peter Ludewig; Gerlinde A S Metz; Axel Montagne; Andre Obenaus; Alex Palumbo; Monica Pearl; Miguel Perez-Pinzon; Anna M Planas; Nikolaus Plesnila; Ami P Raval; Maria A Rueger; Lauren H Sansing; Farida Sohrabji; Charlotte J Stagg; R Anne Stetler; Ann M Stowe; Dandan Sun; Akihiko Taguchi; Mickael Tanter; Sabine U Vay; Raghu Vemuganti; Denis Vivien; Piotr Walczak; Jian Wang; Ye Xiong; Marietta Zille
Journal:  Front Aging Neurosci       Date:  2021-01-28       Impact factor: 5.750

9.  Hippocampal Sector-Specific Metabolic Profiles Reflect Endogenous Strategy for Ischemia-Reperfusion Insult Resistance.

Authors:  Olga Krupska; Tomasz Kowalczyk; Małgorzata Beręsewicz-Haller; Paulina Samczuk; Karolina Pietrowska; Krzysztof Zabłocki; Adam Kretowski; Michal Ciborowski; Barbara Zabłocka
Journal:  Mol Neurobiol       Date:  2020-11-22       Impact factor: 5.590

Review 10.  Mitochondrial MPTP: A Novel Target of Ethnomedicine for Stroke Treatment by Apoptosis Inhibition.

Authors:  Yangxin Li; Jiayi Sun; Ruixia Wu; Jinrong Bai; Ya Hou; Yong Zeng; Yi Zhang; Xiaobo Wang; Zhang Wang; Xianli Meng
Journal:  Front Pharmacol       Date:  2020-03-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.